Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
or

Jaguar Health Inc (JAGX)

Jaguar Health Inc (JAGX)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
4.67 -0.09 (-1.89%) 04/02/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 4.84 +0.17 (+3.64%) 19:48 ET
Quote Overview for Wed, Apr 2nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
4.40
Day High
4.70
Open 4.63
Previous Close 4.76 4.76
Volume 42,100 42,100
Avg Vol 39,942 39,942
Stochastic %K 3.92% 3.92%
Weighted Alpha -84.69 -84.69
5-Day Change -0.46 (-8.97%) -0.46 (-8.97%)
52-Week Range 4.40 - 540.00 4.40 - 540.00
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,123
  • Shares Outstanding, K 656
  • Annual Sales, $ 9,760 K
  • Annual Income, $ -41,300 K
  • EBIT $ -30 M
  • EBITDA $ -14 M
  • 60-Month Beta 1.11
  • Price/Sales 0.27
  • Price/Cash Flow N/A
  • Price/Book 0.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -90.36
  • Growth Rate Est. (year over year) +1,205.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.40 +6.14%
on 04/02/25
Period Open: 15.42
15.75 -70.35%
on 03/03/25
-10.75 (-69.71%)
since 02/28/25
3-Month
4.40 +6.14%
on 04/02/25
Period Open: 27.25
33.25 -85.95%
on 01/06/25
-22.58 (-82.86%)
since 01/02/25
52-Week
4.40 +6.14%
on 04/02/25
Period Open: 111.00
540.00 -99.14%
on 05/03/24
-106.33 (-95.79%)
since 04/02/24

Most Recent Stories

More News
Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules

SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / April 1, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), today announced the closing of its previously announced private placement.

JAGX : 4.67 (-1.89%)
Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules

SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / April 1, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), today announced the closing of its previously announced private placement.

JAGX : 4.67 (-1.89%)
Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023

The total net revenue for the year ended December 31, 2024 of approximately $11.7 million for prescription and non-prescription products, including license revenue, increased approximately 20% versus net...

JAGX : 4.67 (-1.89%)
Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023

The total net revenue for the year ended December 31, 2024 of approximately $11.7 million for prescription and non-prescription products, including license revenue, increased approximately 20% versus net...

JAGX : 4.67 (-1.89%)
83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey

Canalevia®-CA1 (crofelemer delayed-release tablets) is the first and only treatment for CID in dogs to receive any type of approval from the FDA

JAGX : 4.67 (-1.89%)
83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey

Canalevia®-CA1 (crofelemer delayed-release tablets) is the first and only treatment for CID in dogs to receive any type of approval from the FDA

JAGX : 4.67 (-1.89%)
Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study

The statistically significant responder analysis results for Mytesi® (crofelemer) in the OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 poster...

JAGX : 4.67 (-1.89%)
Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study

The statistically significant responder analysis results for Mytesi® (crofelemer) in the OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 poster...

JAGX : 4.67 (-1.89%)
Jaguar Health Presenting March 27 at Emerging Growth Conference and Holding Investor Webcast March 31 Regarding Q4 2024 Financials & Near-Term Catalysts

Click here to register for Jaguar's March 27 virtual presentation at the Emerging Growth Conference

JAGX : 4.67 (-1.89%)
Jaguar Health Presenting March 27 at Emerging Growth Conference and Holding Investor Webcast March 31 Regarding Q4 2024 Financials & Near-Term Catalysts

Click here to register for Jaguar's March 27 virtual presentation at the Emerging Growth Conference

JAGX : 4.67 (-1.89%)
Jaguar Health CEO, Board Members, Other C-Suite Members, and Institutional and Accredited Investors Invest in $3.448 Million Bridge Financing Priced At-The-Market Under Nasdaq Rules

SAN FRANCISCO, CA / ACCESS Newswire / March 26, 2025 / Jaguar Health, Inc.(NASDAQ:JAGX) ("Jaguar" or "the Company"), announced today that Jaguar's president and chief executive officer Lisa Conte, three...

JAGX : 4.67 (-1.89%)
Jaguar Health CEO, Board Members, Other C-Suite Members, and Institutional and Accredited Investors Invest in $3.448 Million Bridge Financing Priced At-The-Market Under Nasdaq Rules

SAN FRANCISCO, CA / ACCESS Newswire / March 26, 2025 / Jaguar Health, Inc.(NASDAQ:JAGX) ("Jaguar" or "the Company"), announced today that Jaguar's president and chief executive officer Lisa Conte, three...

JAGX : 4.67 (-1.89%)
Jaguar Health, Inc. Announces Reverse Stock Split

Reverse split approved at March 2025 Special Meeting of Stockholders

JAGX : 4.67 (-1.89%)
Jaguar Health, Inc. Announces Reverse Stock Split

Reverse split approved at March 2025 Special Meeting of Stockholders

JAGX : 4.67 (-1.89%)
Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders

Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion disease...

JAGX : 4.67 (-1.89%)
Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders

Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion disease...

JAGX : 4.67 (-1.89%)
Jaguar Health Adopts Limited Duration Stockholder Rights Plan to Ensure Stockholders Can Realize Long-Term Value

Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion disease...

JAGX : 4.67 (-1.89%)
Jaguar Health Adopts Limited Duration Stockholder Rights Plan to Ensure Stockholders Can Realize Long-Term Value

Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion disease...

JAGX : 4.67 (-1.89%)
Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease Study - Short Bowel Syndrome with Intestinal Failure (SBS-IF)

This study, initiated yesterday, is one of five clinical efforts - three proof-of-concept (POC) investigator-initiated trials (IIT) and two Phase 2 studies - of crofelemer for the rare disease indications...

JAGX : 4.67 (-1.89%)
Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease Study - Short Bowel Syndrome with Intestinal Failure (SBS-IF)

This study, initiated yesterday, is one of five clinical efforts - three proof-of-concept (POC) investigator-initiated trials (IIT) and two Phase 2 studies - of crofelemer for the rare disease indications...

JAGX : 4.67 (-1.89%)

Business Summary

Jaguar Health, Inc. is a natural-products pharmaceuticals company. It focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals. The company through its subsidiary Napo Pharmaceuticals Inc., focuses on developing and commercializing...

See More

Key Turning Points

3rd Resistance Point 5.08
2nd Resistance Point 4.89
1st Resistance Point 4.78
Last Price 4.67
1st Support Level 4.48
2nd Support Level 4.29
3rd Support Level 4.18

See More

52-Week High 540.00
Fibonacci 61.8% 335.40
Fibonacci 50% 272.20
Fibonacci 38.2% 209.00
Last Price 4.67
52-Week Low 4.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades